245 related articles for article (PubMed ID: 23089896)
1. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
[TBL] [Abstract][Full Text] [Related]
2. P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids.
Hashimoto N; Nakamichi N; Yamazaki E; Oikawa M; Masuo Y; Schinkel AH; Kato Y
Int J Pharm; 2017 Apr; 521(1-2):365-373. PubMed ID: 28242377
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
4. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.
Nagasaka Y; Sano T; Oda K; Kawamura A; Usui T
Xenobiotica; 2014 Oct; 44(10):926-32. PubMed ID: 24666334
[TBL] [Abstract][Full Text] [Related]
7. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
8. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
Nakanishi H; Yonezawa A; Matsubara K; Yano I
Eur J Pharmacol; 2013 Jun; 710(1-3):20-8. PubMed ID: 23588114
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
10. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.
Ito K; Nguyen HT; Kato Y; Wakayama T; Kubo Y; Iseki S; Tsuji A
J Control Release; 2008 Nov; 131(3):198-204. PubMed ID: 18725258
[TBL] [Abstract][Full Text] [Related]
12. Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier.
Robillard KR; Hoque T; Bendayan R
J Pharmacol Exp Ther; 2012 Jan; 340(1):96-108. PubMed ID: 21990609
[TBL] [Abstract][Full Text] [Related]
13. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
Gong IY; Mansell SE; Kim RB
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):164-70. PubMed ID: 22958812
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
15. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
[TBL] [Abstract][Full Text] [Related]
16. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
[TBL] [Abstract][Full Text] [Related]
18. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
19. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
20. Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.
Yousif S; Chaves C; Potin S; Margaill I; Scherrmann JM; Declèves X
J Neurochem; 2012 Nov; 123(4):491-503. PubMed ID: 22845665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
